ArticleClinical sarcoma research2018
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Article in Clinical sarcoma research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.Nature communications · 2022Trial
- MRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis.European radiology · 2025Article
- The Desmoid Dilemma: Challenges and Opportunities in Assessing Tumor Burden and Therapeutic Response.Current oncology (Toronto, Ont.) · 2025Review
- Radial Nerve Palsy Caused by Desmoid-Type Fibromatosis: A Case Report and Review of the Literature.Cureus · 2024Article
- Desmoid Tumors: Current Perspective and Treatment.Current treatment options in oncology · 2024Review
- Benign tumors of the chest wall.Journal of thoracic disease · 2024Review
- Current Treatment Concepts for Extra-Abdominal Desmoid-Type Fibromatosis: A Narrative Review.Cancers · 2024Review
- Desmoid-type fibromatosis: imaging features and course.Skeletal radiology · 2023Review
- Novel insights into biomarkers of progression in Desmoid tumor.Frontiers in oncology · 2023Review
- A Review of the Clinical Presentation, Outcomes, and Treatments of Patients Having Desmoid Tumors.Gastro hep advances · 2023Review
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- Desmoid fibromatosis infiltrating left adrenal gland and kidney.Journal of surgical case reports · 2022Article
- Article
- Evaluation of outcomes in the management of primary sporadic desmoid-type fibromatosis at a specialist soft tissue sarcoma unit.European journal of medical research · 2022Article
- Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.Cancer medicine · 2021Article
- MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.Frontiers in oncology · 2021Article
- Desmoid Tumors Characteristics, Clinical Management, Active Surveillance, and Description of Our FAP Case Series.Journal of clinical medicine · 2020Review
- Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.Pediatric hematology and oncology · 2020Article
- Recent Advances in Desmoid Tumor Therapy.Cancers · 2020Review
- Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.Current oncology (Toronto, Ont.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports.
methodsA retrospective database was used to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. MRI and symptom changes were recorded.
resultsThirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced worsening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. One patient achieved a partial response with improved symptoms.
conclusionsNo relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.